QEEG Clinical Report

EEGLens





The QEEG report is provided by NPCindex Company, operating under the QEEGhome brand.

Personal Data:

Name: Zahra Ranjbari

Gender: Female

Age: 2004-11-12 - 21.2 Handedness: Right

Clinical Data:

Initial diagnosis: Anxiety-Depression-R/O OCD

Medication: -

Date of Recording: 2025-10-15

Source of Referral: Asayesh Psychiatric Clinic - Dr Torabi

This case belongs to Asayesh Psychiatric Clinic - Dr











Z Score Summary Information


Eye Close



Eye Open




Theta/Beta Ratio








Vigilance






EEG Neuromarker Values

APF - EO Frontal 09.75 Normal AFP - EC Frontal 09.50 Normal APF - EO Occipital 10.38 Normal AFP - EC Occipital 09.50 Normal Alpha Asymmetry - EO Frontal -0.04 Anhedonia Alpha Asymmetry - EC Frontal -0.04 Anhedonia Alpha Asymmetry - EO Occipital -0.02 Anhedonia Beta Asymmetry - EC Frontal -0.04 Anxiety Beta Asymmetry - EC Frontal -0.02 Anhedonia Alpha Blocking - - Not Observed Arousal Level - EC - - Normal Vigilance Level - EC - - Normal Vigilance Mean - EC - 05.55 Normal Vigilance Regulation - EC <th>Neuromarker</th> <th>Region</th> <th>Value</th> <th>Assessment</th>	Neuromarker	Region	Value	Assessment
APF - EO	APF - EO	Frontal	09.75	Normal
AFP - EC Occipital 09.50 Normal Alpha Asymmetry - EO Frontal -0.04 Anhedonia Alpha Asymmetry - EC Frontal -0.04 Anhedonia Alpha Asymmetry - EO Occipital 00.01 Anxiety Alpha Asymmetry - EC Occipital -0.02 Anhedonia Beta Asymmetry - EO Frontal -0.04 Anxiety Beta Asymmetry - EC Frontal 00.22 Anhedonia Alpha Blocking - - Not Observed Arousal Level - EO - - Normal Arousal Level - EC - - Normal Vigilance Level - EC - 06.00 Normal Vigilance Mean - EO - 05.55 Normal Vigilance Mean - EC - 00.03 Normal Vigilance Regulation - EO - 00.92 High Vigilance O Stage (%) - EO - 77.39 High Vigilance A1 Stage (%) - EO - 00.00 Normal	AFP - EC	Frontal	09.50	Normal
Alpha Asymmetry - EC Frontal -0.04 Anhedonia Alpha Asymmetry - EC Frontal -0.04 Anhedonia Alpha Asymmetry - EO Occipital 00.01 Anxiety Alpha Asymmetry - EC Occipital -0.02 Anhedonia Beta Asymmetry - EO Frontal -0.04 Anxiety Beta Asymmetry - EC Frontal 00.22 Anhedonia Alpha Blocking - - Not Observed Arousal Level - EO - - Normal Arousal Level - EC - - Normal Vigilance Level - EC - 06.00 Normal Vigilance Level - EC - 03.00 Normal Vigilance Mean - EC - 05.55 Normal Vigilance Mean - EC - 02.81 Normal Vigilance Regulation - EC - 00.03 Normal Vigilance O Stage (%) - EO - 77.39 High Vigilance A1 Stage (%) - EC - 00.00 Normal	APF - EO	Occipital	10.38	Normal
Alpha Asymmetry - EC Frontal -0.04 Anhedonia Alpha Asymmetry - EO Occipital 00.01 Anxiety Alpha Asymmetry - EC Occipital -0.02 Anhedonia Beta Asymmetry - EO Frontal -0.04 Anxiety Beta Asymmetry - EC Frontal 00.22 Anhedonia Alpha Blocking - - Not Observed Arousal Level - EO - - Normal Arousal Level - EC - - Normal Vigilance Level - EO - 06.00 Normal Vigilance Mean - EC - 03.00 Normal Vigilance Mean - EC - 02.81 Normal Vigilance Regulation - EO - 00.03 Normal Vigilance Regulation - EC - 00.92 High Vigilance 0 Stage (%) - EO - 77.39 High Vigilance A1 Stage (%) - EC - 00.00 -	AFP - EC	Occipital	09.50	Normal
Alpha Asymmetry - EC Occipital 00.01 Anxiety Alpha Asymmetry - EC Occipital -0.02 Anhedonia Beta Asymmetry - EO Frontal -0.04 Anxiety Beta Asymmetry - EC Frontal 00.22 Anhedonia Alpha Blocking - Not Observed Arousal Level - EO - Normal Arousal Level - EC - Normal Vigilance Level - EC - Normal Vigilance Level - EC - 03.00 Normal Vigilance Mean - EC - 005.55 Normal Vigilance Regulation - EC - 00.03 Normal Vigilance Regulation - EC - 00.03 Normal Vigilance Regulation - EC - 77.39 High Vigilance 0 Stage (%) - EC - 00.00 Normal Vigilance A1 Stage (%) - EC - 00.00 Normal	Alpha Asymmetry - EO	Frontal	-0.04	Anhedonia
Alpha Asymmetry - EC Occipital -0.02 Anhedonia Beta Asymmetry - EO Frontal -0.04 Anxiety Beta Asymmetry - EC Frontal 00.22 Anhedonia Alpha Blocking - - Not Observed Arousal Level - EO - - Normal Arousal Level - EC - - Normal Vigilance Level - EO - 06.00 Normal Vigilance Level - EC - 03.00 Normal Vigilance Mean - EO - 05.55 Normal Vigilance Mean - EC - 00.03 Normal Vigilance Regulation - EO - 00.92 High Vigilance O Stage (%) - EO - 77.39 High Vigilance O Stage (%) - EC - 00.00 Normal Vigilance A1 Stage (%) - EO - 00.00 -	Alpha Asymmetry - EC	Frontal	-0.04	Anhedonia
Beta Asymmetry - EC Frontal -0.04 Anxiety Beta Asymmetry - EC Frontal 00.22 Anhedonia Alpha Blocking - - Not Observed Arousal Level - EO - - Normal Arousal Level - EC - - Normal Vigilance Level - EC - 06.00 Normal Vigilance Mean - EC - 03.00 Normal Vigilance Mean - EC - 05.55 Normal Vigilance Regulation - EC - 00.03 Normal Vigilance Regulation - EC - 00.92 High Vigilance 0 Stage (%) - EO - 77.39 High Vigilance A1 Stage (%) - EC - 00.00 Normal	Alpha Asymmetry - EO	Occipital	00.01	Anxiety
Beta Asymmetry - EC Frontal 00.22 Anhedonia Alpha Blocking - - Not Observed Arousal Level - EO - - Normal Arousal Level - EC - - Normal Vigilance Level - EO - 06.00 Normal Vigilance Level - EC - 03.00 Normal Vigilance Mean - EO - 05.55 Normal Vigilance Regulation - EC - 00.03 Normal Vigilance Regulation - EC - 00.92 High Vigilance 0 Stage (%) - EO - 77.39 High Vigilance 0 Stage (%) - EC - 00.00 Normal Vigilance A1 Stage (%) - EO - 00.00 -	Alpha Asymmetry - EC	Occipital	-0.02	Anhedonia
Alpha Blocking - - Not Observed Arousal Level - EO - - Normal Arousal Level - EC - - Normal Vigilance Level - EO - 06.00 Normal Vigilance Level - EC - 03.00 Normal Vigilance Mean - EO - 05.55 Normal Vigilance Regulation - EC - 00.03 Normal Vigilance Regulation - EC - 00.92 High Vigilance 0 Stage (%) - EO - 77.39 High Vigilance 0 Stage (%) - EC - 00.00 Normal Vigilance A1 Stage (%) - EO - 00.00 -	Beta Asymmetry - EO	Frontal	-0.04	Anxiety
Arousal Level - EO - - Normal Arousal Level - EC - 06.00 Normal Vigilance Level - EC - 03.00 Normal Vigilance Mean - EC - 05.55 Normal Vigilance Mean - EC - 02.81 Normal Vigilance Regulation - EO - 00.03 Normal Vigilance Regulation - EC - 00.92 High Vigilance 0 Stage (%) - EO - 77.39 High Vigilance 0 Stage (%) - EC - 00.00 Normal Vigilance A1 Stage (%) - EO - 00.00 -	Beta Asymmetry - EC	Frontal	00.22	Anhedonia
Arousal Level - EC - Normal Vigilance Level - EO - 06.00 Normal Vigilance Level - EC - 03.00 Normal Vigilance Mean - EO - 05.55 Normal Vigilance Mean - EC - 02.81 Normal Vigilance Regulation - EO - 00.03 Normal Vigilance Regulation - EC - 00.92 High Vigilance 0 Stage (%) - EO - 77.39 High Vigilance A1 Stage (%) - EO - 00.00 Normal	Alpha Blocking	-	-	Not Observed
Vigilance Level - EO - 06.00 Normal Vigilance Level - EC - 03.00 Normal Vigilance Mean - EO - 05.55 Normal Vigilance Mean - EC - 02.81 Normal Vigilance Regulation - EO - 00.03 Normal Vigilance Regulation - EC - 00.92 High Vigilance 0 Stage (%) - EO - 77.39 High Vigilance 0 Stage (%) - EC - 00.00 Normal Vigilance A1 Stage (%) - EO - 00.00 -	Arousal Level - EO	H	-	Normal
Vigilance Level - EC - 03.00 Normal Vigilance Mean - EO - 05.55 Normal Vigilance Mean - EC - 02.81 Normal Vigilance Regulation - EO - 00.03 Normal Vigilance Regulation - EC - 00.92 High Vigilance 0 Stage (%) - EO - 77.39 High Vigilance 0 Stage (%) - EC - 00.00 Normal Vigilance A1 Stage (%) - EO - 00.00 -	Arousal Level - EC	12	-	Normal
Vigilance Mean - EO - 05.55 Normal Vigilance Mean - EC - 02.81 Normal Vigilance Regulation - EO - 00.03 Normal Vigilance Regulation - EC - 00.92 High Vigilance 0 Stage (%) - EO - 77.39 High Vigilance 0 Stage (%) - EC - 00.00 Normal Vigilance A1 Stage (%) - EO - 00.00 -	Vigilance Level - EO	-	06.00	Normal
Vigilance Mean - EC - 02.81 Normal Vigilance Regulation - EO - 00.03 Normal Vigilance Regulation - EC - 00.92 High Vigilance 0 Stage (%) - EO - 77.39 High Vigilance 0 Stage (%) - EC - 00.00 Normal Vigilance A1 Stage (%) - EO - 00.00 -	Vigilance Level - EC	-	03.00	Normal
Vigilance Regulation - EO - 00.03 Normal Vigilance Regulation - EC - 00.92 High Vigilance 0 Stage (%) - EO - 77.39 High Vigilance 0 Stage (%) - EC - 00.00 Normal Vigilance A1 Stage (%) - EO - 00.00 -	Vigilance Mean - EO	-	05.55	Normal
Vigilance Regulation - EC - 00.92 High Vigilance 0 Stage (%) - EO - 77.39 High Vigilance 0 Stage (%) - EC - 00.00 Normal Vigilance A1 Stage (%) - EO - 00.00 -	Vigilance Mean - EC	-	02.81	Normal
Vigilance 0 Stage (%) - E0 - 77.39 High Vigilance 0 Stage (%) - EC - 00.00 Normal Vigilance A1 Stage (%) - EO - 00.00 -	Vigilance Regulation - EO	-	00.03	Normal
Vigilance 0 Stage (%) - EC - 00.00 Normal Vigilance A1 Stage (%) - EO - 00.00 -	Vigilance Regulation - EC	-	00.92	High
Vigilance A1 Stage (%) – E0 ——————————————————————————————————	Vigilance 0 Stage (%) - E0	-	77.39	High
vigilatios // Stage (s)	Vigilance 0 Stage (%) - EC	<u></u>	00.00	Normal
Vigilance A1 Stage $(\%)$ – EC	Vigilance A1 Stage (%) - E0	-	00.00	-
vigilatice AT Stage (%) – EC	Vigilance A1 Stage (%) - EC	-	10.43	-






EEG Spectra








QEEG Based Predicting Medication Response





Explanation

These two tables can be considered the most important finding that can be extracted from QEEG. To prepare this list, the NPCIndex Article Review Team has studied, categorized, and extracted algorithms from many authoritative published articles on predict medication response and Pharmaco EEG studies. These articles are published between 1970 and 2021. The findings extracted from this set include 85 different factors in the raw band domains, spectrum, power, coherence, and loreta that have not been segregated to avoid complexity, and their results are shown in these diagrams. One can review details in NPCIndex.com .

Medication Recommendation

These two charts, calculate response probability to various medications, according only to QEEG indicators. Blue charts favor drug response and red charts favor drug resistance. The longer the bar, the more evidence there is in the articles. Only drugs listed in the articles are listed. These tables present the indicators reviewed in the QEEG studies and are not a substitute for physician selection.





Report

گزارش:

.1

نتایج تشخیصی:

.1







rTMS Response Prediction

Network Performance


Accuracy: 92.10% Sensitivity: 89.13% Specificity: 97.47%

Participants Information







Features Information



Responsibility



Data Distribution



About Predicting rTMS Response


This index was obtained based on machine learning approaches and by examining the QEEG biomarkers of more than 470 cases treated with rTMS. The cases were diagnosed with depression (with and without comorbidity) and all were medication free. By examining more than 40 biomarkers capable of predicting response to rTMS treatment in previous studies and with data analysis, finally 10 biomarkers including bispectral and nonlinear features entered the machine learning process. The final chart can distinguish between RTMS responsive and resistant cases with 92.1% accuracy. This difference rate is much higher than the average response to treatment of 44%, in the selection of patients with clinical criteria, and is an important finding in the direction of personalized treatment for rTMS.





Pathological Assessment

Main Diagnosis: Anxiety Disorder



Description

According to the guidelines, the initial diagnosis of anxiety disorder could have comorbidities such as **alcohol abuse**, **depression**, **and OCD**. It also differentially diagnoses with **depression and schizophrenia**.

In the above graph, the **red area** shows the percentage of each comorbidity from your patient's EEG markers. Observe that each comorbidity marker is not unique and can be shared with other comorbidities.

Side circles in the above graph represent the differential diagnosis between depression and its misdiagnosis conditions based on your patient's EEG markers and trained artificial intelligence. The differential diagnosis probability is represented by **the bold blue bars** in the circles, and the probability of depression is represented by the gray bars.


Note: In case your patient has drug abuse, obtain the substance abuse pathologic page of QEEGhome by registering the diagnosis under the initial diagnoses section of the website.

References

Sadock, B. J., Sadock, V. A., & Ruiz, P. (Eds.). (2025). Kaplan and Sadock's comprehensive textbook of psychiatry (11th ed., Vols. 1–2). Wolters Kluwer

Sadock, B. J., Sadock, V. A., & Ruiz, P. (2022). Kaplan and Sadock's synopsis of psychiatry: Behavioral sciences/clinical psychiatry (12th ed.). Wolters Kluwer

User Manual








Denoising Information


Eye Close



Rejected Channel



Denoised EEG



Flat Channel



Total Recording Time Remaining:

115.28 sec

Number of Eye and Muscle Elements

Eye: 5 Muscle: 1

Low Artifact Percentage




High Artifact Percentage

Total Artifact Percentage

0

EEG Quality: perfect

Eye Open



Rejected Channel



Total Recording Time Remaining:

182.82 sec

Number of Eye and Muscle Elements

Eye: 3 Muscle: 4

Low Artifact Percentage




High Artifact Percentage



Total Artifact Percentage



EEG Quality: perfect




Flat Channel






Absolute Power-Eye Close




Relative Power-Eye Close








Absolute Power-Eye Open



Relative Power-Eye Open






EEG Quality EC ΕO **Z-score Information** EC EO **■** TMS Reponsibility

Probability

Pathological Assessment



■ EEG Neuromarker Values

Neuromarker	Region	Value	Assessment
APF - EO	Frontal	09.75	Normal
AFP - EC	Frontal	09.50	Normal
APF - EO	Occipital	10.38	Normal
AFP - EC	Occipital	09.50	Normal
Arousal Level - EO	-	-	Normal
Arousal Level - EC	-	-	Normal